Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Acquisitions, Earnings Guidance, Conferences, and Stock Price Updates - Research Report on Express Scripts, Pharmacyclics,



   Acquisitions, Earnings Guidance, Conferences, and Stock Price Updates -
  Research Report on Express Scripts, Pharmacyclics, WellPoint, Stryker, and
                                    Zoetis

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, January 6, 2014

NEW YORK, January 6, 2014 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Express
Scripts Holding Company (NASDAQ: ESRX), Pharmacyclics Inc. (NASDAQ: PCYC),
WellPoint Inc. (NYSE: WLP), Stryker Corp. (NYSE: SYK), and Zoetis Inc. (NYSE:
ZTS). Today's readers may access these reports free of charge - including full
price targets, industry analysis and analyst ratings - via the links below.

Express Scripts Holding Company Research Report

On December 20, 2013, Express Scripts Holding Company (Express Scripts)
announced its plan to release its Q4 2013 earnings and 2014 earnings guidance
on February 20, 2014 after the closing of market. The Company informed that it
has scheduled an investor day meeting in New York City at 8:00 a.m. ET on
February 21, 2014, in which its senior management will review the strategies
to deliver long-term growth and enhance shareholder value, in addition to
discussing Q4 2013 earnings and 2014 earnings guidance. Express Scripts added
that the presentation can be accessed on the Investor Relations section of the
Company website. The Full Research Report on Express Scripts Inc. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/91a7_ESRX

Pharmacyclics Inc. Research Report

On December 31, 2013, Pharmacyclics Inc.'s (Pharmacyclics) stock declined
1.46%, ending the day at $105.78. Over the previous three trading sessions,
shares of Pharmacyclics lost 2.11%, compared to the Nasdaq Composite which
increased 0.23% during the same period. The Full Research Report on
Pharmacyclics Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/df74_PCYC

WellPoint Inc. Research Report

On December 31, 2013, WellPoint Inc.'s (WellPoint) stock rose 0.95%, ending
the day at $92.39. Over the previous three trading sessions, shares of
WellPoint increased 0.26%, compared to the Dow Jones Industrial Average which
rose 0.59% during the same period. The Full Research Report on WellPoint Inc.
- including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/64cd_WLP

Stryker Corp. Research Report    

On December 31, 2013, Stryker Corp. (Stryker) announced a definitive agreement
to acquire Patient Safety Technologies, Inc. (Patient Safety Technologies) for
$2.22 per share, at aggregate purchase price of $120 million. The Company
stated that proprietary Safety-Sponge® System and SurgiCount 360(TM)
compliance software of SurgiCount Medical, Inc., a wholly-owned subsidiary of
Patient Safety Technologies, help to prevent Retained Foreign Objects (RFOs)
in the operating room, resulting in improved patient safety and reduced
healthcare costs. Stryker added that the Safety-Sponge System will become part
of the Company's Instruments division's offerings and will augment its
Instruments' broad portfolio of products. Timothy J. Scannell, Group
President, MedSurg and Neurotechnology, Stryker, commented, "This acquisition
aligns with Stryker's focus on offering products and services that have
demonstrated cost effectiveness and clinical outcomes." The Company stated
that the transaction is subject to customary closing conditions including
approval by the stockholders of Patient Safety Technologies and the expiration
or termination of the Hart-Scott-Rodino Antitrust Improvements Act waiting
period, and is expected to close in Q1 2014. The Full Research Report on
Stryker Corp. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/5b34_SYK

Zoetis Inc. Research Report

On December 20, 2013, Zoetis Inc. (Zoetis) announced that the Company will
host a webcast and conference call at 8:30 a.m. EST on February 11, 2014.
Zoetis added that CEO Juan Ramón Alaix and Executive Vice President and CFO
Rick Passov will review Q4 2013 and full-year 2013 financial results, discuss
2014 financial guidance, and take questions from financial analysts during the
call. The Full Research Report on Zoetis Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

http://www.analystscorner.com/r/full_research_report/7e25_ZTS

EDITOR NOTES:

 1. This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
 2. Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
 3. This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
 4. If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
 5. For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
 6. Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Nidhi Vatsal, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

http://www.AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas, +1-310-496-8071 (North America)
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement